摘要
目的评估血清B7-1和可溶性尿激酶型纤溶酶原激活物受体(suPAR)检测对微小病变肾病(MCD)的诊断价值。方法收集2018年6月至2020年12月郑州大学第一附属医院肾脏内科收治的50例肾活检患者,其中19例MCD患者为观察组,31例其他病理类型患者为对照组。比较两组血清B7-1和suPAR水平,应用SPSS 25.0统计软件分析血清B7-1和suPAR检测诊断MCD的敏感度、特异度和受试者工作特征曲线曲线下面积(AUC)。结果MCD患者血清B7-1和suPAR水平高于对照组(P<0.05)。血清B7-1诊断MCD的敏感度和特异度为89.47%(17/19)、45.16%(14/31)[AUC=0.683(0.530~0.835)],血清suPAR诊断MCD的敏感度和特异度分别为57.89%(11/19)、70.97%(22/31)[AUC=0.681(0.529~0.833)]。联合诊断的结果显示,血清B7-1或suPAR阳性的敏感度为89.47%(17/19),血清B7-1和suPAR阳性的特异度为74.93%(23/31)。结论血清B7-1和suPAR能够有效诊断MCD,两者联合诊断更有临床意义。
Objective To evaluate the diagnostic value of serum B7-1 and soluble urokinase plasminogen activator receptor(suPAR)detection for patients with minimal change disease(MCD).Methods Fifty patients received renal biopsy examination in the Department of Nephrology of the First Affiliated Hospital of Zhengzhou University from June 2018 to December 2020 were collected.Among them,19 MCD patients were selected as the observation group,and 31 non-MCD patients were selected as the control group.The levels of B7-1 and suPAR of the two groups were compared.The SPSS 25.0 software was used to evaluate the sensitivity,specificity and the area under receiver operating characteristic curve(AUC)of serum B7-1 and suPAR in the diagnosis of MCD.Results The levels of serum B7-1 and suPAR in the MCD group were higher than those in the control group(P<0.05).In the diagnosis of MCD,the sensitivity and specificity of serum B7-1 were 89.47%(17/19)and 45.16%(14/31),AUC=0.683(0.530-0.835);while the sensitivity and specificity of serum suPAR were 57.89%(11/19)and 70.97%(22/31),AUC=0.681(0.529-0.833).Results of combination diagnosis showed that the sensitivity of was 89.47%(17/19)when either one of serum B7-1 and suPAR was positive,and the specificity was 74.93%(23/31)when both serum B7-1 and serum suPAR were positive.Conclusions Serum B7-1 and suPAR can effectively serve the diagnosis of MCD,and the combination of serum B7-1 and suPAR may be better than single indicator alone.
作者
袁文明
王春燕
贾宇
王凯
赵占正
Yuan Wenming;Wang Chunyan;Jia Yu;Wang Kai;Zhao Zhanzheng(Department of Nephrology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)
出处
《中国实用医刊》
2022年第19期67-70,共4页
Chinese Journal of Practical Medicine
